Navigation Links
Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
Date:2/9/2016

SAN FRANCISCO, February 9, 2016 /PRNewswire/ --

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it will be a featured presenting company at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference which takes place on February 10-11, 2016 in New York City. The Company's presentation will be given on Wednesday, February 10, 2016 at 12:30 pm by Gerald E. Commissiong, President & CEO of Amarantus, in the OneMedMarket Venture Track. The presentation will provide an update on the Company's regulatory interactions with FDA. Amarantus' CEO will be available for one-on-one meetings at the conference.

About Amarantus BioScience Holdings, Inc. 

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. More recently, AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard) that led to MANF's discovery.

For further information please visit http://www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Forward-Looking Statements 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Investor and Media Contact:
Ascendant Partners, LLC
Fred Sommer
+1-732-410-9810
fred@ascendantpartnersllc.com


'/>"/>
SOURCE Amarantus Bioscience Holdings, Inc
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
2. Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
3. Amarantus to Present at ICV Sonoma Event
4. Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
5. Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
6. Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
7. Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinsons Disease Levodopa-induced Dyskinesia (PD-LID)
8. Amgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference
9. Aethlon Medical to Present at Source Capital Groups 2016 Disruptive Growth & Healthcare Conference on February 10, 2016
10. Cryoport to Present at the Source Capital Groups 2016 Disruptive Growth & Healthcare Conference
11. Delcath Systems to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2019)... ... 2019 , ... LuckyVitamin, an e-commerce specialty retailer and manufacturer ... Healthiest Employers of 2019. LuckyVitamin’s Founder and Chief Wellness Spreader, Sam Wolf, along ... at the Ballroom at the Ben on June 13, 2019. , This highly ...
(Date:6/19/2019)... ... 19, 2019 , ... Advocates for Physicians’ Rights (AFPR), a ... protection of physicians’ rights, asserts that the recent SB 276 Amendments encroach on ... narrow guidelines as a basis for issuing legitimate medical exemptions. , “The ...
(Date:6/19/2019)... OBISPO, Calif. (PRWEB) , ... June 19, 2019 , ... “We sometimes take out teeth ... and flossing, and regular checkups we seldom think about our teeth unless it’s baby’s first ... teeth help us chew, speak, smile and have a very important role in our overall ...
Breaking Medicine Technology:
(Date:6/24/2019)... ... 2019 , ... Cibo Vita, Inc., makers of Nature’s Garden, NutriPops, Chocolate Orchard ... indulgence snack line at the 65th annual Summer Fancy Food Show, taking place at ... booth #5721. , The company’s expansive product portfolio features a variety of trail ...
(Date:6/20/2019)... ... , ... Access Healthcare, one of the largest providers of ... appointed as Senior Vice President of Client Services. Angel brings more than 20 ... high performing teams, and driving revenue growth for healthcare companies. , In this ...
(Date:6/19/2019)... (PRWEB) , ... June 19, ... ... from non-governmental organizations, academia, faith-based organizations, private institutions, media, and government joined ... DC to make commitments to improve universal access to water, sanitation, and ...
(Date:6/19/2019)... , ... June 19, 2019 , ... A legal-medical ... the United States, has filed class action lawsuits in 34 of the 48 ... in the class actions are an array of pharmaceutical manufacturers, distributors and retailers, all ...
(Date:6/19/2019)... ... June 19, 2019 , ... Ovation® Fertility scientists have been invited ... Reproduction and Embryology (ESHRE) Annual Meeting in Vienna, June 23-26, 2019. , Ovation’s ... consideration for both the Basic Science Award for Oral Presentation and the Fertility Society ...
Breaking Medicine News(10 mins):